keyword
MENU ▼
Read by QxMD icon Read
search

QALY

keyword
https://www.readbyqxmd.com/read/28738456/-cost-effectiveness-of-community-based-treatment-of-chronic-hepatitis-b-in-china
#1
S X Zhang, P C Yang, Y L Cai, Y Lin, Y H Zou
Objective: Since eliminating hepatitis B in China would need considerable public health resources, the economics problem of the strategy of community-based antiviral treatment for chronic hepatitis B (CHB) has become an important issue. The cost-effectiveness and affordability of the strategy were evaluated in this study. Methods: According to the advocacy on eliminating hepatitis B by WHO and the comprehensive protocol of community based prevention of major infectious diseases and the guideline for CHB prevention and treatment in China, the decision analytic Markov model was constructed with the parameters from national surveys or Meta-analysis...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28738455/-cost-effectiveness-and-affordability-of-strategy-for-preventing-mother-to-child-transmission-of-hepatitis-b-in-china
#2
Y Lin, S X Zhang, P C Yang, Y L Cai, Y H Zou
Objective: To evaluate the cost effectiveness of nationwide prevention of mother to child transmission (PMTCT) strategy for hepatitis B, and estimate the willing to pay and budget impacts on the PMTCT. Methods: The decision analytic Markov model for the PMTCT was constructed and a birth cohort of Chinese infants born in 2013 was used to calculate the cost-effectiveness of the PMTCT among them compared with those receiving no intervention. The parameters in the model were obtained from literatures of national surveys or Meta-analysis...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28736623/a-literature-review-of-cost-effectiveness-of-intravenous-recombinant-tissue-plasminogen-activator-for-treating-acute-ischemic-stroke
#3
Heesoo Joo, Guijing Wang, Mary G George
BACKGROUND: Intravenous recombinant tissue plasminogen activator (IV rtPA) is recommended treatment for acute ischemic stroke patients, but the cost-effectiveness of IV rtPA within different time windows after the onset of acute ischemic stroke is not well reviewed. AIMS: To conduct a literature review of the cost-effectiveness studies about IV rtPA by treatment times. SUMMARY OF REVIEW: A literature search was conducted using MEDLINE, EMBASE, CINAHL and Cochrane Library, with the key words acute ischemic stroke, tissue plasminogen activator, cost, economic benefit, saving, and incremental cost-effectiveness analysis...
2017: Stroke and Vascular Neurology
https://www.readbyqxmd.com/read/28736418/the-complicated-relationship-of-disability-and-well-being
#4
Stephen M Campbell, Joseph A Stramondo
It is widely assumed that disability is typically a bad thing for those who are disabled. Our purpose in this essay is to critique this view and defend a more nuanced picture of the relationship between disability and well-being. We first examine four interpretations of the above view and argue that it is false on each interpretation. We then ask whether disability is thereby a neutral trait. Our view is that most disabilities are neutral in one sense, though we cannot make simple generalizations about disability's relationship to well-being in other important senses...
2017: Kennedy Institute of Ethics Journal
https://www.readbyqxmd.com/read/28732684/the-impact-of-current-infection-levels-on-the-cost-benefit-of-vaccination
#5
Matt J Keeling, Katherine A Broadfoot, Samik Datta
When considering a new vaccine programme or modifying an existing one, economic cost-benefit analysis, underpinned by predictive epidemiological modelling, is a key component. This analysis is intimately linked to the willingness to pay for additional QALYs (quality-adjusted life-years) gained; currently in England and Wales a health programme is economically viable if the cost per QALY gained is less than £ 20,000, and models are often used to assess if a vaccine programme is likely to fall below this threshold cost...
July 8, 2017: Epidemics
https://www.readbyqxmd.com/read/28732620/results-and-methodology-of-cost-utility-evaluation-of-cataract-surgery-in-developed-countries-quality-adjusted-life-years-and-cataract
#6
REVIEW
Ursula Hahn, Frank Krummenauer
This review surveyed the results and methods of cost-utility analyses of cataract surgery. Thirteen studies were included. Based on decision-theoretic time trade-off, utilities ranged from 0.148 to 0.8 and quality-adjusted life years (QALY) ranged from 1.424 to 2.43. Based on psychometric instruments such as Euroqol 5 dimensions, utilities ranged from 0.017 to 0.056 and QALY ranged from 0.141 to 0.547. Reported costs per QALY were between $1307 and $14 302. Although the review found consistent favorable cost QALY ratios for cataract surgery according to the British National Institute for Care and Health Excellence threshold, the findings raise doubts about the general applicability of existing studies as a tool for allocation decision...
June 2017: Journal of Cataract and Refractive Surgery
https://www.readbyqxmd.com/read/28732590/cost-utility-of-evaluation-for-posterior-vitreous-detachment-and-prophylaxis-of-retinal-detachment
#7
Nicolas A Yannuzzi, Jonathan S Chang, Gary C Brown, William E Smiddy
PURPOSE: To evaluate the costs and cost-utility of examination for posterior vitreous detachment (PVD) and treatment of associated pathology, and of managing various other peripheral retinal disorders to prevent retinal detachment (RD). DESIGN: A decision analysis model of cost-utility. PARTICIPANTS: There were no participants. METHODS: Published retrospective data on the natural course of PVD, retinal tears, and lattice degeneration were used to quantitate the visual benefits of examination and treatment...
July 18, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28729321/economic-evaluation-of-a-brief-counselling-for-smoking-cessation-in-dentistry-a-case-study-comparing-two-health-economic-models
#8
Suvi Erika Virtanen, Maria R Galanti, Pia M Johansson, Inna Feldman
OBJECTIVES: This study aimed to compare the cost-effectiveness estimates of a brief counselling of smoking cessation in dentistry by using two different health economic models. DESIGN AND OUTCOME MEASURES: Intervention effectiveness was estimated in a cluster randomised controlled trial. The number of quitters was estimated based on 7-day abstinence and on smoking reduction at follow-up. Health economic evaluation was performed using two models: (1) a population-based model employing potential impact fractions and (2) a Markov model estimating the cost-effectiveness of the intervention for the actual participants...
July 20, 2017: BMJ Open
https://www.readbyqxmd.com/read/28726530/incremental-net-monetary-benefit-of-ocrelizumab-relative-to-subcutaneous-interferon-%C3%AE-1a
#9
Melissa A Frasco, Tiffany Shih, Devin Incerti, Oliver Diaz Espinosa, Diana K Vania, Nina Thomas
AIM: Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of an emerging DMT, ocrelizumab, was quantified in comparison to subcutaneous interferon beta-1a (IFNβSC) for the prevalent RRMS population with mild to moderate disability in the United States based on two Phase 3 trials, OPERA I and OPERA II, of ocrelizumab versus IFNβSC in RRMS...
July 20, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28723754/an-economic-analysis-of-high-dose-imatinib-dasatinib-and-nilotinib-for-imatinib-resistant-chronic-phase-chronic-myeloid-leukemia-in-china-a-cheers-compliant-article
#10
Bin Wu, Maobai Liu, Te Li, Houwen Lin, Hua Zhong
BACKGROUND: The aim of the study was to test the cost-effectiveness of dasatinib compared to high-dose imatinib and nilotinib in Chinese patients who were diagnosed with imatinib-resistant chronic myeloid leukemia in the chronic phase (CML-CP). METHODS: A Markov model combined with clinical effectiveness, utility, and cost data was used. The sensitivity analyses were conducted to determine the robustness of the model outcomes. The impact of patient assistance programs (PAPs) was assessed...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28721059/cost-effectiveness-analysis-of-dolutegravir-plus-backbone-compared-with-raltegravir-plus-backbone-darunavir-ritonavir-plus-backbone-and-efavirenz-tenofovir-emtricitabine-in-treatment-na%C3%A3-ve-and-experienced-hiv-positive-patients
#11
Umberto Restelli, Giuliano Rizzardini, Andrea Antinori, Adriano Lazzarin, Marzia Bonfanti, Paolo Bonfanti, Davide Croce
BACKGROUND: In January 2014, the European Medicines Agency issued a marketing authorization for dolutegravir (DTG), a second-generation integrase strand transfer inhibitor for HIV treatment. The study aimed at determining the incremental cost-effectiveness ratio (ICER) of the use of DTG+backbone compared with raltegravir (RAL)+backbone, darunavir (DRV)+ritonavir(r)+backbone and efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC) in HIV-positive treatment-naïve patients and compared with RAL+backbone in treatment-experienced patients, from the Italian National Health Service's point of view...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28720631/accrued-cost-savings-of-a-free-clinic-using-quality-adjusted-life-years-saved-and-return-on-investment
#12
Jim Sanders, Marcus Lacey, Clare E Guse
INTRODUCTION: Savings garnered through the provision of preventive services is a form of profit for health systems. Free clinics have been using this logic to demonstrate their cost-savings. The Community-Based Chronic Disease Management (CCDM) clinic treats hypertension using nurse-led teams, clinical protocols, and community-based settings. METHODS: We calculated CCDM's cost-effectiveness from 2007 to 2013 using 2 metrics: Quality-adjusted life years (QALYs) saved and return on investment (ROI)...
July 2017: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/28720054/impact-of-novel-agents-on-patient-relevant-outcomes-in-patients-with-previously-untreated-cll-who-are-not-eligible-for-fludarabine-based-therapy
#13
Moushmi Singh, Stuart Mealing, Simona Baculea, Sarah Cote, Jo Whelan
BACKGROUND: Chronic lymphocytic leukemia (CLL) is an orphan disease that primarily affects the elderly. The majority of symptomatic patients eligible for frontline treatment are unfit for fludarabine based chemoimmunotherapy. Historical treatment includes chlorambucil (Chl), bendamustine/rituximab (BR), and chlorambucil/rituximab/ChlR combination. Clinical guidelines now recommend the use of novel agents, such as ibrutinib (Ibr), in both frontline and relapse settings and other novel agents, such as idelalisib (with rituximab), in relapse settings...
July 19, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28719013/in-an-era-of-highly-effective-treatment-hepatitis-c-screening-of-the-general-population-of-the-united-states-for-hepatitis-c-should-be-considered
#14
Zobair Younossi, Deidre Blissett, Rob Blissett, Linda Henry, Youssef Younossi, Rachel Beckerman, Sharon Hunt
BACKGROUND AND AIMS: Hepatitis C virus (HCV) treatment with all oral direct acting antiviral agents (DAA's) achieve sustained virologic response (SVR) rates of 98%. Re-assessment of general US population screening for HCV is imperative. This study compared the cost-effectiveness (CE) of three HCV screening strategies: screen all (SA), screen Birth Cohort (BCS), and screen high risks (HRS). METHODS: Using a previous designed decision-analytic Markov model, estimations of the natural history of HCV and CE evaluation of the three HCV screening strategies over a lifetime horizon in the US population was undertaken...
July 18, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28718981/health-economic-analysis-of-allergen-immunotherapy-ait-for-the-management-of-allergic-rhinitis-asthma-food-allergy-and-venom-allergy-a-systematic-overview
#15
REVIEW
Miqdad Asaria, Sangeeta Dhami, Ronald van Ree, Roy Gerth van Wijk, Antonella Muraro, Graham Roberts, Aziz Sheikh
BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is developing guidelines for allergen immunotherapy (AIT) for the management of allergic rhinitis, allergic asthma, IgE-mediated food allergy and venom allergy. To inform the development of clinical recommendations, we undertook systematic reviews to critically assess evidence on the effectiveness, safety and cost-effectiveness of AIT for these conditions. This paper focusses on synthesizing data and gaps in the evidence on the cost-effectiveness of AIT for these conditions...
July 18, 2017: Allergy
https://www.readbyqxmd.com/read/28718037/cost-effectiveness-of-surveillance-for-distant-recurrence-in-extremity-soft-tissue-sarcoma
#16
Trevor J Royce, Rinaa S Punglia, Aileen B Chen, Sagar A Patel, Katherine A Thornton, Chandrajit P Raut, Elizabeth H Baldini
BACKGROUND: Optimal distant recurrence (DR) surveillance strategies for extremity soft tissue sarcoma (STS) are unknown. We performed a cost-effectiveness analysis of different imaging modalities performed at guideline-specified intervals. METHODS: We developed a Markov model simulating lifetime outcomes for 54-year-old patients after definitive treatment for American Joint Committee on Cancer stage II-III extremity STS using four surveillance strategies: watchful waiting (WW), chest X-ray (CXR), chest computed tomography (CCT), and positron emission tomography-computed tomography (PET/CT)...
July 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28717701/cost-effectiveness-of-universal-hepatitis-b-virus-screening-in-patients-beginning-chemotherapy-for-sarcomas-or-gi-stromal-tumors
#17
Glorijoy Tan, Ke Zhou, Chee Hian Tan, David B Matchar, Mohamad Farid, Richard Quek, Joanne Ngeow
PURPOSE: The value of screening for hepatitis B virus (HBV) infection before chemotherapy for nonhematopoietic solid tumors remains unsettled. We evaluated the cost effectiveness of universal screening before systemic therapy for sarcomas, including GI stromal tumors (GISTs). PATIENTS AND METHODS: Drawing from the National Cancer Centre Singapore database of 1,039 patients with sarcomas, we analyzed the clinical records of 485 patients who received systemic therapy...
August 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717246/estimating-utility-weights-and-quality-adjusted-life-year-loss-for-colorectal-cancer-related-health-states-in-korea
#18
Jin Yong Lee, Minsu Ock, Min-Woo Jo, Woo-Seung Son, Hyeon-Jeong Lee, Seon-Ha Kim, Hyun Joo Kim, Jong Lyul Lee
We aimed to assess utility weight of health states associated with colorectal cancer (CRC) that reflect the societal preference of the Korean population and to estimate the quality-adjusted life year (QALY) loss with CRC. We recruited 607 individuals from the Korean population; they were surveyed via face-to-face computer-assisted interviews. The participants evaluated each CRC-associated health state using standard gamble. Utility weight for each health state was calculated as the possibility of full health restoration...
July 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28716519/cost-effectiveness-of-simvastatin-plus-ezetimibe-for-cardiovascular-prevention-in-patients-with-a-history-of-acute-coronary-syndrome-analysis-of-results-of-the-improve-it-trial
#19
Ziyad S Almalki, Jeff Jianfei Guo, Abdullah Alahmari, Nawaf Alotaibi, Hilal Thaibah
BACKGROUND: Simvastatin plus ezetimibe reduced the risk of cardiovascular events in the IMProved Reduction of Outcomes: Vytorin Efficacy International (IMPROVE-IT) study. The aim of this study is to investigate the cost-effectiveness of adding ezetimibe to simvastatin treatment for patients with ACS based on the recently completed IMPROVE-IT trial. METHODS: We constructed a Markov state-transition model to evaluate the costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness (ICER) associated with co-therapy compared with simvastatin alone from a health care perspective...
June 15, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28716508/routine-intraoperative-cholangiography-during-cholecystectomy-is-a-cost-effective-approach-when-analysing-the-cost-of-iatrogenic-bile-duct-injuries
#20
Jenny M L Rystedt, Bobby Tingstedt, Fredrik Montgomery, Agneta K Montgomery
BACKGROUND: The total cost of bile duct injuries (BDIs) in an unselected national cohort of patients undergoing cholecystectomy are unknown. The aim was to evaluate costs associated with treatment of cholecystectomy-related BDIs and to calculate cost effectiveness of routine vs. on-demand intraoperative cholangiography (IOC). METHODS: Data from Swedish patients suffering a BDI during a 5 year period were analysed. Questionnaires to investigate loss-of-production and health status (EQ-5D) were distributed to patients who suffered a BDI during cholecystectomy and who underwent uneventful cholecystectomy (matched control group)...
July 14, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
keyword
keyword
18154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"